Brilinta Tablets and Nevirapine Oral Suspension
Determining the interaction of Brilinta Tablets and Nevirapine Oral Suspension and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Nevirapine may reduce the blood levels of ticagrelor in some patients, which may make the medication less effective in preventing blood clots, heart attack, or stroke. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:GENERALLY AVOID: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of ticagrelor, which is primarily metabolized by the isoenzyme. In 14 healthy volunteers, administration of a single 180 mg oral dose of ticagrelor on day 12 of treatment with the potent CYP450 3A4 inducer rifampin (600 mg once daily for 14 days) decreased mean ticagrelor peak plasma concentration (Cmax), systemic exposure (AUC) and plasma half-life by 73%, 86% and 67%, respectively, compared to administration of ticagrelor alone. Mean Cmax of the major active metabolite was unchanged in the presence of rifampin, but mean AUC decreased by 46% and plasma half-life by 50%. Inhibition of platelet aggregation (IPA) was also assessed in the study. Mean IPA at 12 hours was 87% with ticagrelor alone versus 63% in combination with rifampin; corresponding values at 24 hours were 70% and 15%, respectively. It is not known to what extent ticagrelor may interact with weak and moderate CYP450 3A4 inducers.
MANAGEMENT: Concomitant use of ticagrelor with CYP450 3A4 inducers should generally be avoided. Otherwise, caution is advised, and patients should be closely monitored for diminished clinical response to ticagrelor therapy. Alternative treatment may be required if an interaction is suspected.
- "Product Information. Brilinta (ticagrelor)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.
- Weeks P, Sieg A, Vahdat K, Raissi F, Nathan S "Improved ticagrelor antiplatelet effect on discontinuation of phenytoin." Ann Pharmacother 48 (2014): 644-7
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Teng R, Mitchell P, Butler K "Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects." Eur J Clin Pharmacol 69 (2013): 877-83
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
Generic Name: ticagrelor
Brand name: Brilinta
Synonyms: Brilinta
Generic Name: nevirapine
Brand name: Viramune, Viramune XR
Synonyms: Nevirapine
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Brilinta Tablets-Nevirapine Suspension
- Brilinta Tablets-Nevirapine Tablets
- Brilinta Tablets-New Day
- Brilinta Tablets-New Terocin
- Brilinta Tablets-Nexa Plus
- Brilinta Tablets-Nexa Select
- Nevirapine Oral Suspension-Brimonidine
- Nevirapine Oral Suspension-Brimonidine and brinzolamide ophthalmic
- Nevirapine Oral Suspension-Brimonidine and Timolol
- Nevirapine Oral Suspension-Brimonidine and timolol ophthalmic
- Nevirapine Oral Suspension-Brimonidine ophthalmic
- Nevirapine Oral Suspension-Brimonidine Tartrate eent